Yamamoto T, Fukuda K, Morita A, et al. - Researchers tested the effectiveness of guselkumab in the subset of patients with pustulotic arthro‐osteitis (PAO) in this exploratory analysis of a double‐blind, multicenter, placebo‐controlled, phase 3 study in Japanese patients with palmoplantar pustulosis (PPP). Participants in the study were randomized to receive guselkumab 100 mg or 200 mg at weeks 0, 4, 12, and every 8 weeks, or placebo with cross‐over to guselkumab 100 mg or 200 mg at week 16 (placebo group). Of the 159 patients with PPP, 66 with PAO have been randomized across treatment groups. Treatment with guselkumab exhibited beneficial outcomes for signs and symptoms of PAO in Japanese patients with PPP.